An update on the efficacy of mouthwash use

25 November, 2022 / editorial
 

On 10 October, Johnson & Johnson Ltd., the makers of Listerine®, hosted a press briefing at Ogilvy & Mather Sea Containers in London to provide an update on the efficacy of mouthwash use. The event was chaired by Professor Iain Chapple, Professor of Periodontology and Consultant in Restorative Dentistry, Birmingham UK, who explored why it is time to take gingivitis seriously, focusing on the human, economic and societal cost of periodontal disease.

Adding to Professor Chapple’s insight were presentations from:

• Professor Elena Figuero, Full-Professor in Periodontology at the University Complutense of Madrid (Spain), who joined via video link to discuss the efficacy of adjunctive therapies in reducing plaque by means of a systematic review of randomised clinical trials (1,2) who said: “The overall idea that should be kept in mind is that higher biofilm reductions might be achieved when antiseptics are used as an adjunct to self-performed mechanical biofilm control procedures (toothbrushing or interdental devices) compared to these same mechanical procedures alone.”

• Benjamin Tighe, a dental therapist in private practice and a Tutor Dental Therapist at The Eastman Dental Hospital, who spoke about his experience of recommending mouthwash for plaque management purposes in practice.

• Soha Dattani, a periodontist and Head of Professional at Johnson & Johnson, who shared the latest data from new Johnson & Johnson trials, which were peer reviewed and published in the American ‘Journal of Dental Hygiene’ earlier this year. (3,4)

Soha Dattani, Benjamin Tighe and Professor Iain Chapple.

This invaluable meeting served as the culmination of 12 months of activity for Johnson and Johnson Ltd., which involved both the National Advisory Panel and Hygienist Advisory Panel gatherings and their subsequent consensuses statements on mouthwash use, as well as the dissemination of new data revealing how to tackle interproximal plaque with essential oils-based LISTERINE®.(3,4)

Bringing all of these threads together for a full overview, the results from the peer reviewed studies were shared. The published results report that for patients who brush and floss, adding LISTERINE® reduces interproximal plaque by 28.4 per cent versus brushing and flossing alone.*4 And, for those who don’t floss, adjunctive use of LISTERINE® reduced interproximal plaque above the gumline by 4.6x versus floss.**3

Frequently asked questions, see: www.sdmag.co.uk/2022/11/25/mouthwash-research-questions/

For further information, visit listerineprofessional.co.uk

* Sustained plaque reduction above the gumline with continual twice daily use for 12 weeks after a dental cleaning. Flossing underwent once daily supervision on weekdays. Use LISTERINE® as part of a 3-step routine.

** Sustained plaque reduction above the gumline with continual twice daily use for 12 weeks after a dental cleaning. Flossing was performed by a dental hygienist.

References

1. Figuero E et al. Efficacy of adjunctive anti-plaque chemical agents in managing gingivitis: A systematic review and network meta-analyses. J Clin Periodontol 2019; 46(7): 723-739

2. Figuero E et al. Efficacy of adjunctive therapies in patients with gingival inflammation: A systematic review and meta-analysis. J Clin Periodontol 2020; 47: 125-143

3. Bosma ML et al. Efficacy of flossing and mouthrinsing regimens on plaque and gingivitis: A randomized clinical trial. Journal of Dental Hygiene 2022; 96(3): 8-20

4. Milleman J et al. Comparative effectiveness of toothbrushing, flossing and mouthrinse regimens on plaque and gingivitis: a 12-week virtually supervised clinical trial. Journal of Dental Hygiene 2022; 96(3): 21-34

Tags: Listerine

Categories: Professional Focus

Comments are closed here.

Scottish Dental magazine